Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 9/20 | 0.46 |
| ▸ | DRD4 | P21917 | 6/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534084 | 0.95 | DRD3 (0.47) | ACACBDRD3DRD4DRD2HTR1A | |
| SCHEMBL3245091 | 0.83 | SLC6A4 (0.52) | DRD3DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL20178679 | 0.80 | ACACB (0.59) | ACACBPRMT5WDR77 | |
| SCHEMBL3243957 | 0.80 | SLC6A4 (0.51) | DRD3DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL1797089 | 0.79 | ACACB (0.49) | ACACBDRD3DRD4DRD2HTR1A | |
| SCHEMBL13255332 | 0.79 | DRD2 (0.52) | DRD3DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL5534030 | 0.78 | HTR7 (0.43) | DRD3DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL3245085 | 0.78 | DRD2 (0.51) | ACACBDRD3DRD2HTR1AHTR2A | |
| SCHEMBL5535345 | 0.78 | CARM1 (0.48) | ACACBDRD3DRD4DRD2SLC6A4 | |
| SCHEMBL3246829 | 0.78 | ABCB1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | claimed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | claimed |
| US-7311893-B2 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | disclosed |
| EP-1303311-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | Neurochem, Inc. (CA) | 2003-04-23 | — | — | EP | disclosed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | disclosed |
| WO-2002007781-A2 | AMYLOID TARGETING IMAGING AGENTS AND USES THEREOF | NEUROCHEM INC. (CA) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ACACB 2318/4885DRD3 3595/4885DRD4 3652/4885 |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ACACB 2318/4885DRD3 3595/4885DRD4 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.